Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
- Conditions
- Choroidal Neovascularization (CNV)
- Interventions
- Other: Sham control
- First Posted Date
- 2013-04-25
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 183
- Registration Number
- NCT01840410
- Locations
- 🇹🇷
Novartis Investigative Site, Kocaeli, Turkey
Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2016-08-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01837927
A Study to Assess the Effect of QAW039 in Non-atopic Asthmatic Patients
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2013-04-22
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 345
- Registration Number
- NCT01836471
- Locations
- 🇿🇦
Novartis Investigative Site, Pretoria, South Africa
A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 25
- Registration Number
- NCT01836458
- Locations
- 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: fluticasone/salmeterol
- First Posted Date
- 2013-04-18
- Last Posted Date
- 2013-11-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT01834885
- Locations
- 🇩🇪
Novartis Investigative Site, Rheine, Germany
BKM120 for Patients With PI3K-activated Tumors
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 146
- Registration Number
- NCT01833169
- Locations
- 🇺🇸
Arizona Oncology Associates PC- HAL, Sedona, Arizona, United States
🇺🇸Bend Memorial Clinic Bend Mem. Clinic, Bend, Oregon, United States
🇺🇸Eastern Connecticut Hematology & Oncology Associates The Norwich Cancer Center, Norwich, Connecticut, United States
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib
- Conditions
- Tumor Pathway Activations Inhibited by Dovitinib
- Interventions
- First Posted Date
- 2013-04-15
- Last Posted Date
- 2017-03-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT01831726
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
🇺🇸Cleveland Clinic Foundation Cleveland Clinic (19), Cleveland, Ohio, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies
- Conditions
- Hematological Malignancies
- First Posted Date
- 2013-04-11
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 23
- Registration Number
- NCT01830010
- Locations
- 🇨🇭
Novartis Investigative Site, Zürich, Switzerland
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 231
- Registration Number
- NCT01828112
- Locations
- 🇺🇸
Uni Of Iowa Hospitals And Clinics, Iowa, Iowa, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸Memorial Cancer Institute, Hollywood, Florida, United States
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT01828099
- Locations
- 🇬🇧
Novartis Investigative Site, Nottingham, United Kingdom